Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Allarity Therapeutics, Inc. - Common stock
(NQ:
ALLR
)
0.2228
+0.0289 (+14.90%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Allarity Therapeutics, Inc. - Common stock
< Previous
1
2
Next >
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
July 26, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
July 24, 2024
From
The Schall Law Firm
Via
Business Wire
Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALLR
July 24, 2024
From
Rosen Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 24, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Allarity Therapeutics Inc. (NASDAQ: ALLR) Near the Top of Equities by Percentage Gain on 4/12
April 12, 2024
Via
Investor Brand Network
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 24, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
July 24, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Allarity Therapeutics, Inc. (ALLR) on Behalf of Investors
July 23, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
July 22, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
June 27, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
June 25, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
May 14, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
May 07, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 06, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
May 02, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
April 17, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
April 04, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
March 27, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
March 25, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
March 08, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics to Present at Biomarkers 2024
February 28, 2024
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
December 12, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
December 05, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics to Present at Biomarkers Europe 2023
October 02, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology
September 14, 2023
Via
ACCESSWIRE
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
August 30, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
July 31, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
July 24, 2023
From
Allarity Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.